Lytix Biopharma AS announced that it has completed recruitment of 20 patients in the ATLAS-IT-05 trial - a trial evaluating LTX-315, Lytix' lead drug candidate. The ATLAS-IT-05 trials is designed to assess the efficacy of LTX-315 in patients with advanced melanoma, who are refractory to treatment with anti-PD-1/PD-L1 inhibitors. LTX-315 is being studied in combination with the immune checkpoint inhibitor pembrolizumab, which blocks tumor cells' ability to prevent the body's immune response.

Results from earlier studies indicate that the combination of LTX-315 and pembrolizumab may work better than pembrolizumab alone. The first patient in this trial was enrolled in December 2021, at MD Anderson Cancer Center in Houston, Texas - one of the world's leading cancer hospitals. A total of 10 sites have been involved in this study - 4 in the US and 6 in Europe.

Enrolled patients receive treatment with LTX-315 for up to 5 weeks. Pembrolizumab therapy will continue until disease progression or 24 months after enrollment.